4D Molecular Therapeutics shares rise 30.44% premarket after presenting positive 60-week results for 4D-150.

4d Molecular Therapeutics, Inc. rose 30.44% in premarket trading, driven by positive 60-week results from 4D-150. The company reported that 4D-150 was well tolerated with no intraocular inflammation observed, and demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and anatomic control. The Phase 3 dose achieved a clinically meaningful 78% reduction in treatment burden. Additionally, the EMA aligned with the proposed single Phase 3 clinical trial being acceptable for regulatory submission for 4D-150 in DME, consistent with previously announced alignment with the FDA.